Trading Update

AI SummaryClose X

OptiBiotix Health plc reported a strong financial performance for the year ended 31 December 2025, with sales orders increasing by 33% to £1.34 million and revenue rising 30% to £1.13 million. Gross profit saw a significant 82% jump to £603,000, with the gross profit margin improving to 53% from 38% in the prior year, while operating costs remained stable at £2.6 million. The company ended the year with a cash balance of £1.03 million and holdings in ProBiotix Health Plc and SkinBioTherapeutics Plc valued at £6.45 million. Looking ahead, OptiBiotix is focusing on commercial sustainability through significant cost reductions, anticipated to save £500,000-£600,000 annually, and margin improvements expected to reduce SlimBiome production costs by up to 48%. The company also reported a record start to 2026 with over £800,000 in orders received in January.

Disclaimer*

UK 100

Latest directors dealings